News
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for ...
The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in ...
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
The Department of Justice’s 2025 national health care fraud investigation resulted in hundreds of defendants nationwide being ...
With the FDA recently rejecting a drug application that aims to help those living with Barth Syndrome, one Bay Area family is ...
Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...
The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults ...
A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...
A common drug used for inflammatory skin conditions may hold the key to treating both alcohol addiction and pain sensitivity.
Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results